Understanding Pain in Veterinary Oncology: Mechanisms, Types, and Clinical Relevance

Pain in animals, particularly in oncologic patients, has transitioned from being underestimated to becoming a central focus in veterinary clinical care. Historically, there was a misconception that animals either did not perceive pain or experienced it differently from humans. However, advances in neurobiology have firmly established that animals possess similar neural pathways for pain perception, making effective pain management not just a therapeutic goal but an ethical obligation in veterinary practice¹. 

The Clinical Importance of Pain in Oncology Patients 

Pain is not merely a symptom in cancer patients; it is a complex physiological and pathological process that significantly influences recovery, immune function, and overall quality of life. In animals with cancer, pain can lead to metabolic disturbances, behavioral changes, and reduced physiological resilience, ultimately compromising treatment outcomes¹. More importantly, unrelieved pain has been shown to negatively affect the immune system, potentially creating an environment conducive to tumor progression and metastasis². 

From a clinical standpoint, veterinarians must recognize that pain management is not only about improving comfort but also about influencing disease trajectory. Animals with chronic oncologic pain often exhibit reduced mobility, appetite changes, altered social behavior, and diminished interaction with their environment, all of which signal declining welfare¹. Therefore, early recognition and proactive management of pain are critical in oncology cases. 

Nociception: The Foundation of Pain Perception 

At the core of pain lies nociception, the physiological process through which painful stimuli are detected and transmitted to the brain. This process begins with the activation of peripheral nociceptors, which respond to mechanical, thermal, or chemical stimuli. These signals are carried via Aδ and C nerve fibers to the central nervous system, where they are processed and interpreted as pain^1,3. 

Understanding nociception allows veterinarians to adopt a targeted approach to analgesia. By identifying where along this pathway the pain signal can be modulated—whether peripherally, spinally, or centrally, clinicians can design more effective, individualized treatment protocols. This becomes particularly important in cancer patients, where pain mechanisms are often multifactorial and dynamic. 

Types of Pain: Why Classification Matters in Practice 

Effective pain management begins with correctly identifying the type of pain involved. In veterinary oncology, pain is not uniform and can present in multiple forms, each requiring a tailored therapeutic approach. 

Acute or “First Pain” is typically associated with tissue injury or inflammation. It is short-lived, localized, and often serves a protective function by prompting the animal to avoid further harm. In clinical settings, acute pain is commonly seen post-surgery or during invasive diagnostic procedures. Multimodal analgesia is particularly effective here, combining opioids with adjunct drugs such as NSAIDs or NMDA receptor antagonists to enhance efficacy and reduce side effects¹. 

Chronic or “Second Pain”, on the other hand, is persistent and often pathological. It arises from prolonged activation of pain pathways, leading to central sensitization, a condition where the central nervous system becomes hypersensitive to stimuli¹. This type of pain is commonly observed in long-standing cancer cases and is associated with significant impairment in quality of life. Unlike acute pain, chronic pain does not offer any biological advantage and requires a comprehensive, long-term management strategy. 

Neuropathic Pain results from damage to the nervous system itself, either peripheral or central. It is notoriously difficult to manage, as it often shows limited response to conventional analgesics like NSAIDs and some opioids. Recognizing neuropathic pain is crucial, as it may necessitate the use of specific agents such as methadone, which has additional NMDA receptor antagonist properties^1,4. 

Visceral Pain originates from internal organs and is often diffuse and poorly localized. In oncologic patients, it may arise from tumor infiltration or organ distension. This type of pain requires a targeted approach that addresses both the underlying cause and the pain pathway¹. 

Somatic Pain, which can be either superficial or deep, arises from skin, muscles, or connective tissues. While superficial somatic pain is usually well-localized, deep somatic pain tends to be more diffuse and challenging to pinpoint¹. Both forms are commonly encountered in cancer patients with soft tissue or musculoskeletal involvement. 

Pain Sensitization: The Hidden Amplifier 

One of the most critical yet often underappreciated aspects of pain in oncology is sensitization. Peripheral sensitization occurs when nociceptors become more responsive due to inflammatory mediators, while central sensitization involves increased excitability of neurons in the central nervous system¹. 

These processes lead to phenomena such as hyperalgesia (increased response to painful stimuli) and allodynia (pain from normally non-painful stimuli), both of which complicate pain management. In practical terms, this means that even minor stimuli can trigger significant pain responses in cancer patients, making early and aggressive pain control essential. 

Pathophysiology of Cancer Pain 

Cancer pain is multifaceted, involving direct tumor effects, inflammatory responses, and treatment-related factors. Tumors can invade surrounding tissues and nerves, disrupting normal signaling pathways and causing persistent pain^5,6. Additionally, cancer cells release various mediators such as prostaglandins, cytokines, and growth factors that sensitize nociceptors and amplify pain signals. 

Chemotherapeutic agents further contribute to pain by inducing neuronal damage and altering ion channel function, leading to increased neuronal excitability¹. This combination of factors makes oncologic pain particularly complex and difficult to manage with a single therapeutic approach. 

Clinical Implications for Veterinarians 

For practicing veterinarians, the key takeaway is that pain in oncologic patients is dynamic, multifactorial, and deeply interconnected with overall health outcomes. A one-size-fits-all approach is insufficient. Instead, clinicians must adopt a multimodal and individualized strategy, considering the type of pain, underlying pathology, and the animal’s overall condition. 

Equally important is the use of validated pain assessment tools, which correlate behavioral and physiological indicators with pain intensity. These tools enable more objective evaluation and help guide treatment decisions. 

Conclusion 

Pain in veterinary oncology is far more than a symptom, it is a critical determinant of patient welfare and clinical outcomes. With growing evidence highlighting the similarities between human and animal pain mechanisms, veterinarians are now better equipped to understand and manage pain effectively. By integrating knowledge of nociception, pain types, and underlying pathophysiology, clinicians can deliver more precise, compassionate, and effective care to their oncologic patients. 

Reference 

1. Pinheiro AV, Petrucci GN, Dourado A, Silva F, Pires I. Pain Management in Animals with Oncological Disease: Opioids as Influencers of Immune and Tumor Cellular Balance. Cancers. 2024 Aug 29;16(17):3015. https://doi.org/10.3390/cancers16173015 

2. Gültekin Ç. Comparison of the analgesic effects of morphine and tramadol after tumor surgery in dogs. Open Veterinary Journal. 2021 Nov 9;11(4):613. https://pmc.ncbi.nlm.nih.gov/articles/PMC8770189/pdf/OpenVetJ-11-613.pdf 

3. Treede RD. The International Association for the Study of Pain definition of pain: as valid in 2018 as in 1979, but in need of regularly updated footnotes. Pain reports. 2018 Mar 1;3(2):e643. https://journals.lww.com/painrpts/FullText/2018/04000/The_International_Association_for_the_Study_of.2.aspx 

4. Finnerup NB, Kuner R, Jensen TS. Neuropathic pain: from mechanisms to treatment. Physiological reviews. 2021 Jan 1;101(1):259-301. https://journals.physiology.org/doi/pdf/10.1152/physrev.00045.2019?download=true 

5. Wang H, Zheng Q, Lu Z, Wang L, Ding L, Xia L, Zhang H, Wang M, Chen Y, Li G. Role of the nervous system in cancers: a review. Cell death discovery. 2021 Apr 12;7(1):76. https://www.nature.com/articles/s41420-021-00450-y.pdf 
6. Santoni A, Santoni M, Arcuri E. Chronic cancer pain: opioids within tumor microenvironment affect neuroinflammation, tumor and pain evolution. Cancers. 2022 Apr 30;14(9):2253. https://www.mdpi.com/2072-6694/14/9/2253